ACADIA Pharmaceuticals (ACAD) is an undervalued small-cap stock that is developing advanced technology related to two common ailments that cause psychosis in the elderly, Alzheimer's and Parkinson's. Additionally, the company is using the same platform to develop a treatment for schizophrenia. Longer term projects include treatments for chronic pain and glaucoma and broader treatments for Parkinson's disease. Based on market and company research a price target of $25 for sometime between July 2014 and December 2014 is a realistic and achievable goal for the stock.
THE AGING POPULATION DRIVES A GROWING MARKET
There is no way around the fact that in major industrialized nations the population is aging and afflictions and diseases that affect this demographic are...
Only subscribers can access this article, which is part of the PRO research library covering 3,773 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: